Treatment of Irritable Bowel Syndrome

Initial Management and Patient Education

The American Gastroenterological Association recommends establishing a positive diagnosis using Rome criteria without extensive testing in patients under 45 years without alarm features, avoiding unnecessary investigations that undermine patient confidence 2
The National Institute for Health and Care Excellence suggests explaining IBS as a disorder of gut-brain interaction with a benign but relapsing-remitting course, introducing the concept of how diet, stress, and emotional responses affect the gut-brain axis 3, 1
The American College of Gastroenterology recommends implementing regular physical exercise for all IBS patients as this provides significant benefits for global symptom management 1, 4

The British Dietetic Association provides initial dietary counseling focusing on identifying and reducing excessive intake of lactose, fructose, sorbitol, caffeine, or alcohol 2, 4
The American Gastroenterological Association recommends starting soluble fiber (ispaghula/psyllium) at 3-4 g/day, gradually increasing to 25 g/day to avoid bloating, while avoiding insoluble fiber (wheat bran) which worsens symptoms 1, 2
The National Institute for Health and Care Excellence suggests considering a supervised low FODMAP diet trial (10+ weeks for restriction and reintroduction phases) delivered by a trained dietitian for patients with persistent symptoms after 4 weeks of standard dietary advice 3, 1, 2
The American College of Gastroenterology recommends trialing probiotics for 12 weeks and discontinuing if no improvement in global symptoms, bloating, or abdominal pain 1, 2

The American Gastroenterological Association recommends prescribing loperamide 4-12 mg daily (either regularly or prophylactically) as the most effective first-line treatment to reduce stool frequency, urgency, and fecal soiling 1, 2, 4
The National Institute for Health and Care Excellence suggests considering rifaximin as second-line therapy, though its effect on abdominal pain is limited 3, 1
The American College of Gastroenterology recommends trialing cholestyramine for patients with prior cholecystectomy or suspected bile acid malabsorption (approximately 10% of IBS-D patients) 2, 4

The British Dietetic Association recommends beginning with polyethylene glycol (osmotic laxative), titrating dose according to symptoms, with abdominal pain being the most common side effect 1
The National Institute for Health and Care Excellence suggests using stimulant laxatives (senna) as first-line therapy, recognizing limited specific evidence in IBS-C but reasonable based on efficacy in general constipation 3
The American Gastroenterological Association recommends prescribing linaclotide (secretagogue) as the preferred second-line agent when first-line therapies fail after 4-6 weeks, as it is the most effective option for IBS-C with strong evidence 1

The American College of Gastroenterology recommends starting antispasmodics with anticholinergic properties (dicyclomine, hyoscine) for meal-exacerbated pain, though dry mouth, visual disturbance, and dizziness are common side effects 3, 1, 2
The National Institute for Health and Care Excellence suggests trialing peppermint oil as an alternative antispasmodic with fewer side effects 3, 1

The American Gastroenterological Association recommends initiating tricyclic antidepressants (amitriptyline 10 mg once daily at bedtime) for refractory pain and global symptoms, titrating slowly to 30-50 mg daily over at least 6 months if effective 3, 1, 2
The National Institute for Health and Care Excellence suggests using selective serotonin reuptake inhibitors (SSRIs) as alternatives when TCAs are not tolerated or when concurrent mood disorder is present 3, 1, 2

The American Psychological Association recommends referring for IBS-specific cognitive behavioral therapy or gut-directed hypnotherapy when symptoms persist despite 12 months of pharmacological treatment 3, 1, 2, 4
The National Institute for Health and Care Excellence suggests considering mindfulness-based stress reduction (8-12 sessions) for patients with prominent psychological stress and negative emotion 3

The American Gastroenterological Association recommends reviewing treatment efficacy after 3 months and discontinuing ineffective medications 1, 2
The National Institute for Health and Care Excellence suggests continuing TCAs for at least 6 months if the patient reports symptomatic improvement 3, 1
The American College of Gastroenterology recommends recognizing that complete symptom resolution is often not achievable; manage patient expectations by explaining that treatment aims for symptom relief and improved quality of life, not cure 3, 1

The American Gastroenterological Association recommends avoiding opioids for chronic abdominal pain management due to risks of dependence, complications, and potential worsening of constipation 3
The National Institute for Health and Care Excellence suggests recognizing frequent comorbidity with mental health disorders (anxiety, depression) and considering referral to gastropsychology when symptoms are moderate to severe and the patient accepts gut-brain dysregulation as a contributing factor 3, 2